Skip to main content

Table 3 Comparative costs (US$) for first-line treatment of MCRC with XELOX and FOLFOX4 from a healthcare payer perspective

From: Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement

   XELOX
(n = 30)
Mean (SD)
FOLFOX4
(n = 30)
Mean (SD)
Scheduled costs per cycle
Chemotherapy cost 1,184 (152) 724 (84)
Hospital days for chemotherapy delivery 180 (-)* 848 (-)*
Hospital tests 55 (106) 76 (163)
Outpatient visits 155 (52) 135 (46)
Outpatient tests at scheduled visits 472 (291) 368 (191)
Total scheduled cost per cycle 2,046 (325) 2,152 (307)
Total scheduled cost per patient 14,866 (3,823) 19,801 (5,405)
Other unscheduled costs
Drug costs 4 (7) 44 (191)
Hospital days 201 (355) 355 (670)
Outpatient visits 15 (21) 13 (39)
Outpatient tests at unscheduled visits 20 (53) 9 (28)
Total unscheduled cost per cycle 240 (364) 421 (890)
Total unscheduled cost per patient 1,743 (2,197) 3,871 (3,870)
Total cost per patient 16,609 (4,710) 23,672 (5,904)
  1. * These are estimated rather than measured (see methods) therefore no SD is calculated.